Heart failure

Q: What does the research say about Heart failure?

The scientific consensus on Heart failure is unassessed. 100 primary claims are on file, but none have been compared for agreement or contradiction yet. Based on 100 analyzed claims.

Q: What do clinical guidelines recommend for Heart failure?

Current guideline recommendations: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality. | Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations. | Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. | Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

What the evidence says about Heart failure

Synthesized from 31 evidence-backed clinical questions linked to this topic — 11 supporting the intervention, 20 against the intervention.

Where the evidence lands

31 questions

The placed evidence leans toward harm

Favor benefit

35% of all

Favor harm

65% of all

BenefitHarm

Moderate For13%
Weak For1032%
Weak Against2065%

Strength of that evidence

31 questions

Low certainty on 97% of questions

Moderate13%
Low3097%

Does empagliflozin vs placebo improve outcomes in Heart failure?

Moderate Certainty+ Favors benefit

empagliflozin vs placebo · Myopathy / Rhabdomyolysis

46 studies (226,117 patients, 1 RCTs) provide moderate-certainty evidence for benefit of empagliflozin for Myopathy / Rhabdomyolysis in Heart failure.

Moderate evidence for1 RCT · 226,117 patients

Does sacubitril / valsartan vs enalapril improve outcomes in Heart failure?

Low Certainty− Favors harm

sacubitril / valsartan vs enalapril · Heart Failure Hospitalization

24 studies (76,300 patients, 1 RCTs) provide low-certainty evidence against benefit of sacubitril / valsartan for Heart Failure Hospitalization in Heart failure.

Actively debated

Does omecamtiv mecarbil vs placebo improve outcomes in Heart failure?

Low Certainty− Favors harm

omecamtiv mecarbil vs placebo · All-Cause Mortality

11 studies (23,527 patients) provide low-certainty evidence against benefit of omecamtiv mecarbil for All-Cause Mortality in Heart failure.

Weak evidence against11 studies · 23,527 patients↻ Reversal

What does the research say about Heart failure?

Unassessed pathwayBased on 100 analyzed claims

100 primary claims are on file, but none have been compared for agreement or contradiction yet.

Journal clubs discussing Heart failure

Recent sessions

ANDROMEDA, ATHENA and PALLAS

Cardiology Trials Journal Club — Tue, Aug 25, 10:00 AM EDT

Inflammatory Hypothesis of CAD

STEMI Management — Wed, Aug 12, 8:00 AM EDT — 7 attended

Frontiers in Precision Medicine Journal Club | Opening Session

Cornell - Precision Medicine — Fri, Jul 3, 12:00 PM EDT — 1 attended

Sessions from public journal clubs on Synapse. RSVP to join the live discussion.

New research on Heart failure

β-Blocker therapy for heart failure

Current Opinion in Cardiology — Slatton M — May 1996

Read paper

C ase R eport . Use of Noninvasive Hemodynamics to Aid Decision Making in the Initiation and Titration of Neurohormonal Agents

Congestive Heart Failure — Summers R — Mar 2004

Read paper

What can we learn from Europe?

Heart — Swedberg K — Apr 2005

Read paper

Review of the new ESC guidelines for the pharmacological management of chronic heart failure

European Heart Journal Supplements — Maggioni A — Oct 2005

Read paper

Stay current on Heart failure

Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.

Journal Club takes on Heart failure

Evidence brief: Heart failure

Heart failure (also known as HF, CHF, congestive heart failure). General heart failure research and clinical updates

As of 2026-10-01, the scientific consensus on Heart failure is unassessed. 100 primary claims are on file, but none have been compared for agreement or contradiction yet. Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

Major professional bodies have published 4 guideline recommendations on Heart failure. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/heart-failure.

Deterministic synthesis from Synapse's enriched corpus — 213 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

What do clinical guidelines recommend for Heart failure?

Class ILOE A

In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.

Class ILOE A

In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.

Class ILOE A

In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.

Class ILOE A

In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.